Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18639758 | KAVA COMPOSITIONS AND METHODS OF USE | April 2024 | May 2025 | Abandon | 13 | 2 | 0 | No | No |
| 18511152 | METHOD OF MAKING SILVER NANOPARTICLES CAPPED WITH CARALLUMA SINAICA EXTRACT AND TREATMENT METHOD USING THE SAME | November 2023 | December 2024 | Allow | 13 | 2 | 0 | No | No |
| 18389181 | ANTIBIOTIC WITH SPIRULINA PLATENSIS AND PLANT EXTRACTS | November 2023 | November 2024 | Abandon | 12 | 2 | 0 | No | No |
| 18213022 | KAVA COMPOSITIONS AND METHODS OF USE | June 2023 | March 2025 | Allow | 20 | 3 | 1 | Yes | Yes |
| 18338002 | METHODS OF DEPOSITING SILVER NANOSTRUCTURES ON TO IMPLANT SURFACES | June 2023 | December 2024 | Allow | 18 | 1 | 0 | No | No |
| 18133240 | CANNABINOID AND SUGAR ALCOHOL COMPLEX, METHODS TO MAKE AND USE | April 2023 | January 2025 | Abandon | 21 | 0 | 1 | No | No |
| 18129182 | METHODS OF DIAGNOSING AND TREATING DRY EYE SYNDROME AND COMPOSITIONS FOR TREATING A HUMAN EYE | March 2023 | September 2024 | Allow | 18 | 1 | 0 | No | No |
| 18107544 | METHOD OF REDUCING MUSCLE DAMAGE ASSOCIATED WITH INTENSIVE EXERCISE BY ADMINISTERING PURPLE-TEA EXTRACT | February 2023 | September 2024 | Allow | 19 | 1 | 0 | No | No |
| 18102541 | AGGREGATING MICROPARTICLES FOR MEDICAL THERAPY | January 2023 | January 2025 | Abandon | 24 | 1 | 0 | No | No |
| 18146973 | MICROARRAY FOR DELIVERY OF THERAPEUTIC AGENT AND METHODS OF USE | December 2022 | January 2025 | Abandon | 25 | 1 | 1 | No | No |
| 18053224 | DISINFECTANTS WITH IODINE AND COPPER COMPLEXES | November 2022 | July 2024 | Allow | 20 | 1 | 0 | No | No |
| 17947793 | ANTIBIOTIC WITH SPIRULINA PLATENSIS AND PLANT EXTRACTS | September 2022 | August 2023 | Abandon | 11 | 3 | 1 | No | No |
| 17810363 | POLYGONI MILLETII RHIZOME COMPOSITIONS AND METHODS OF PREPARING THE SAME | July 2022 | December 2024 | Allow | 29 | 2 | 0 | Yes | No |
| 17841364 | MEDICAL TABLET, AND MANUFACTURING METHOD AND MANUFACTURING APPARATUS FOR MEDICAL TABLET | June 2022 | November 2024 | Abandon | 29 | 1 | 0 | No | No |
| 17834014 | SUSTAINED RELEASE FORMULATION COMPRISING OCTREOTIDE AND TWO OR MORE POLYLACTIDE-CO-GLYCOLIDE POLYMERS | June 2022 | December 2024 | Abandon | 31 | 2 | 1 | No | No |
| 17828557 | Method of Providing Oral Care Benefits | May 2022 | March 2025 | Abandon | 33 | 2 | 1 | No | No |
| 17728041 | MODIFIED HERBAL COMPOSITIONS FOR NEUROMODULATION | April 2022 | November 2024 | Allow | 31 | 3 | 1 | Yes | No |
| 17721445 | COMPOSITIONS OF FLUOROCARBON NANOEMULSION, AND METHODS OF PREPARATION AND USE THEREOF | April 2022 | March 2025 | Abandon | 35 | 4 | 0 | No | No |
| 17720720 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF PRE-DIABETES, DIABETES AND METABOLIC SYNDROME | April 2022 | May 2025 | Abandon | 37 | 0 | 1 | No | No |
| 17640147 | Electrically Conductive Hydrogels Usable As Lead Extensions, Apparatus For Delivery Of A Hydrogel Into The Vasculature, and Methods Of Treating Ventricular Arrhythmia With Electrically Conductive Hydrogels Injected In The Venous System | March 2022 | June 2025 | Allow | 39 | 1 | 1 | No | No |
| 17674642 | COMPOSITIONS AND METHODS FOR SUPPORTING IMMUNE HEALTH | February 2022 | August 2024 | Allow | 30 | 2 | 1 | No | No |
| 17627524 | SKIN CARE COMPOSITONS COMPRISING SYNERGISTIC BLEND OF SACRED LOTUS AND TEA PLANT OR SACRED LOTUS AND GERMAN CHAMOMILE AND COSMETIC APPLICATIONS THEREOF | January 2022 | March 2025 | Allow | 38 | 1 | 1 | No | No |
| 17626859 | WATER-IN-OIL EMULSION COMPOSITION FOR ENHANCED DELIVERY OF WATER SOLUBLE SKIN BENEFIT AGENTS | January 2022 | March 2025 | Abandon | 38 | 1 | 0 | No | No |
| 17625752 | COMPOSITIONS, MEANS AND METHODS FOR A NOVEL INSECT REPELLENT | January 2022 | March 2025 | Abandon | 38 | 1 | 0 | No | No |
| 17623922 | PHARMACEUTICAL COMPOSITION OF DAROLUTAMIDE | December 2021 | April 2025 | Allow | 39 | 1 | 1 | No | No |
| 17555258 | COMPOSITIONS AND METHODS FOR INHIBITING YEAST INFECTIONS | December 2021 | October 2024 | Abandon | 34 | 3 | 1 | No | No |
| 17619474 | COMPOSITION COMPRISING METFORMIN HCI, VITAMIN B12 AND AT LEAST ONE FLOW ADDITIVE | December 2021 | March 2025 | Abandon | 39 | 0 | 1 | No | No |
| 17596627 | DEGRADABLE REGENERATIVE MEDICAL MATERIAL FOR PROMOTING TISSUE IN-SITU REGENERATION AND PREPARATION METHOD THEREFOR | December 2021 | May 2025 | Allow | 41 | 1 | 1 | No | No |
| 17616569 | METHODS AND COMPOSITIONS FOR MICROFLILLNG THE SKIN WITH HYALURONIC ACID USING MICROCHANNEL TECHNOLOGY | December 2021 | February 2025 | Abandon | 39 | 0 | 1 | No | No |
| 17612258 | FREEZE-RESISTANT DISINFECTANT COMPOSITION AND PREPARATION METHOD THEREFOR | November 2021 | March 2025 | Allow | 40 | 1 | 1 | No | No |
| 17494598 | HERBAL FORMULATION AND METHOD OF ADMINISTERING THE SAME | October 2021 | November 2024 | Abandon | 37 | 4 | 0 | No | No |
| 17435568 | Composition for Increasing Occupancy of Faecalibacterium in Intestinal Flora | September 2021 | March 2025 | Abandon | 43 | 2 | 0 | Yes | No |
| 17408646 | DELIVERY PARTICLE | August 2021 | May 2024 | Allow | 33 | 3 | 0 | No | No |
| 17339618 | AMANTADINE COMPOSITIONS, PREPARATIONS THEREOF, AND METHODS OF USE | June 2021 | June 2024 | Allow | 37 | 2 | 1 | No | No |
| 17288392 | TOPICAL COMPOSITION COMPRISING AN INORGANIC UV-FILTER | April 2021 | December 2024 | Abandon | 44 | 0 | 1 | No | No |
| 16077722 | DRUG-LOADED TISSUE ADHESIVE FILM AND PREPARATION METHOD THEREFOR | April 2021 | December 2024 | Abandon | 60 | 2 | 0 | No | No |
| 17285711 | Sublingual Epinephrine Compositions Including pH-Modifying Excipients And Penetration Enhancers And Methods for Use Thereof | April 2021 | March 2025 | Allow | 47 | 2 | 1 | No | No |
| 17272756 | AN IRON CONTAINING COMPOSITION AND USE THEREOF | March 2021 | September 2024 | Allow | 43 | 2 | 1 | No | No |
| 17271150 | THERAPEUTIC COMBINATIONS OF BOSWELLIA EXTRACT AND CANNABINOIDS | February 2021 | December 2024 | Abandon | 45 | 1 | 1 | No | No |
| 17269497 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER CELLS BY INDUCTION OF CYTOTOXIC OXIDATIVE STRESS | February 2021 | January 2025 | Allow | 47 | 2 | 1 | No | No |
| 17250559 | Pet Food Compositions | February 2021 | March 2025 | Allow | 49 | 4 | 1 | Yes | No |
| 17263600 | INORGANIC-ORGANIC HYBRID COMPOUNDS INCLUDING ORGANIC PLATINUM-CONTAINING ANIONS, FOR USE IN MEDICINE | January 2021 | July 2024 | Allow | 42 | 2 | 1 | No | No |
| 17059233 | SINGLE CELL ENCAPSULATION VIA PICKERING EMULSION FOR BIO-PESTICIDES APPLICATION | November 2020 | November 2024 | Allow | 48 | 2 | 1 | Yes | No |
| 17059221 | METHOD FOR ENHANCING EMBRYO IMPLANTATION | November 2020 | September 2024 | Allow | 46 | 3 | 1 | Yes | No |
| 17044377 | TREATMENT OF INFECTIONS CAUSED BY NEISSERIA GONOCOCCUS USING A HALOGENATED SALICYLANILIDE | October 2020 | September 2024 | Allow | 48 | 3 | 1 | No | No |
| 17039426 | Composition for the Modulation of Circadian Rhythmicity and Sleep Quality | September 2020 | December 2024 | Abandon | 50 | 4 | 1 | No | No |
| 16873552 | Process for making aqueous therapeutic particle having stable exterior water clustering with nanosized thickness | April 2020 | March 2025 | Allow | 58 | 4 | 1 | Yes | No |
| 16647976 | Conductive Graphene/Carbon Nanofiber Composite Scaffold, its use for neural tissue engineering and a method of preparation thereof | March 2020 | December 2024 | Allow | 57 | 3 | 1 | No | No |
| 16631184 | NEW KIND OF WOUND DRESSING FOR HAEMOSTASIS | January 2020 | September 2024 | Allow | 57 | 4 | 1 | Yes | No |
| 16731870 | HAIR COLORING COMPOSITIONS AND METHODS OF USE | December 2019 | November 2024 | Allow | 58 | 2 | 0 | No | Yes |
| 16448927 | SOLID PHARMACEUTICAL FORMULATIONS OF ASIMADOLINE | June 2019 | October 2024 | Allow | 60 | 7 | 0 | Yes | Yes |
| 16162060 | Compositions and Methods to Enhance Ultrasound-Mediated Delivery of Pharmaceutical Agents | October 2018 | May 2025 | Abandon | 60 | 8 | 1 | Yes | No |
| 15682764 | CHEMICALLY STABLE COMPOSITIONS OF A PHARMACEUTICAL ACTIVE AGENT IN A MULTI-CHAMBERED DELIVERY SYSTEM FOR MUCOSAL DELIVERY | August 2017 | July 2019 | Allow | 23 | 2 | 1 | Yes | No |
| 15096957 | Method of Treating Multiple Sclerosis | April 2016 | September 2018 | Allow | 29 | 3 | 1 | Yes | No |
| 14899039 | CATIONIC GROUP-CONTAINING CELLULOSE ETHER | December 2015 | September 2017 | Allow | 21 | 1 | 1 | Yes | No |
| 14934135 | METHODS AND COMPOSITIONS RELATED TO SYNTHETIC NANOCARRIERS WITH RAPAMYCIN IN A STABLE, SUPER-SATURATED STATE | November 2015 | November 2024 | Abandon | 60 | 9 | 1 | Yes | Yes |
| 14877916 | METHOD OF TREATING DIABETIC WOUNDS USING BIOSYNTHESIZED NANOPARTICLES | October 2015 | June 2016 | Allow | 8 | 3 | 1 | Yes | No |
| 14774255 | APPLICATION OF BIOFILM FORMATION INHIBITING COMPOUNDS ENHANCES CONTROL OF CITRUS CANKER | September 2015 | June 2018 | Allow | 44 | 3 | 1 | Yes | No |
| 14796928 | BIOLOGICAL INFORMATION ACQUISITION METHOD AND INSTRUMENT, AND PHYSIOLOGICALLY-ACTIVE SUBSTANCE MEASUREMENT METHOD AND INSTRUMENT | July 2015 | April 2016 | Allow | 10 | 1 | 0 | No | No |
| 14605265 | BIOACTIVE LOAD-BEARING COMPOSITES | January 2015 | February 2016 | Allow | 13 | 1 | 0 | No | No |
| 14537764 | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | November 2014 | June 2016 | Allow | 20 | 1 | 1 | Yes | No |
| 14382985 | SILICON DIOXIDE IN SHAVING PRODUCTS | September 2014 | September 2015 | Allow | 13 | 0 | 0 | Yes | No |
| 14458625 | METHOD OF TREATING MULTIPLE SCLEROSIS | August 2014 | December 2015 | Allow | 16 | 0 | 1 | Yes | No |
| 14376595 | COMPOSITIONS FOR INCREASING HAIR GROWTH | August 2014 | January 2016 | Allow | 17 | 1 | 0 | Yes | No |
| 14337776 | VASCULAR CLOSURE DEVICE | July 2014 | November 2014 | Allow | 3 | 0 | 0 | Yes | No |
| 14238605 | INTERPOLYMER NETWORK DELIVERY SYSTEM | June 2014 | July 2016 | Allow | 29 | 2 | 1 | Yes | No |
| 14362115 | SILICA MICROCAPSULES, PROCESS OF MAKING THE SAME AND USES THEREOF | May 2014 | January 2016 | Allow | 20 | 0 | 0 | No | No |
| 14238774 | METHODS FOR IMPROVING THE BIOACTIVITY CHARACTERISTICS OF A SURFACE AND OBJECTS WITH SURFACES IMPROVED THEREBY | April 2014 | December 2015 | Allow | 22 | 1 | 1 | Yes | No |
| 14258119 | IC31 NANOPARTICLES | April 2014 | November 2015 | Allow | 19 | 1 | 0 | Yes | No |
| 14136460 | STRUCTURED DEPILATORY COMPOSITIONS | December 2013 | July 2015 | Allow | 19 | 1 | 1 | Yes | No |
| 14058640 | HYDROSWELLABLE, SEGMENTED, ALIPHATIC POLYURETHANES AND POLYURETHANE UREAS | October 2013 | January 2015 | Allow | 15 | 1 | 0 | Yes | No |
| 14053796 | Coating Layers For Medical Devices And Method Of Making The Same | October 2013 | June 2015 | Allow | 20 | 4 | 0 | No | No |
| 14047442 | INGESTIBLE CANKER SORE TREATMENT | October 2013 | January 2015 | Allow | 15 | 1 | 1 | Yes | No |
| 14028990 | Transdermal therapeutic system with crystallization-inhibiting protective film (Release liner) | September 2013 | February 2015 | Allow | 17 | 1 | 0 | Yes | No |
| 13939528 | DRUG DELIVERY SYSTEM | July 2013 | September 2014 | Allow | 14 | 1 | 0 | Yes | No |
| 13937363 | MEDICAL DEVICES WITH GALVANIC PARTICULATES | July 2013 | February 2015 | Allow | 19 | 1 | 0 | Yes | No |
| 13737992 | FATTY ACIDS FOR USE AS A MEDICAMENT | January 2013 | January 2015 | Allow | 24 | 2 | 1 | Yes | No |
| 13698775 | DISINFECTANT COMPOSITION FOR HARD ARTICLES, AND METHOD FOR DISINFECTING OF SURFACE OF HARD ARTICLE | November 2012 | September 2014 | Allow | 22 | 0 | 0 | Yes | No |
| 13657585 | METHODS AND COMPOSITIONS FOR TREATING MUCOSITIS | October 2012 | August 2014 | Allow | 22 | 2 | 1 | Yes | Yes |
| 13510116 | NOVEL COMPOUND | October 2012 | July 2014 | Allow | 26 | 1 | 1 | Yes | No |
| 13607401 | METHODS FOR PRODUCING SILVER-BONDED ANTIMICROBIAL MOIST WOUND DRESSINGS AND MOIST WOUND DRESSINGS PRODUCED BY THE METHODS | September 2012 | December 2012 | Allow | 3 | 0 | 0 | Yes | No |
| 13598405 | Methods of Manufacturing Viscous Liquid Pharmaceutical Formulations | August 2012 | April 2017 | Allow | 55 | 5 | 1 | Yes | No |
| 13578686 | IC31 NANOPARTICLES | August 2012 | February 2014 | Allow | 18 | 1 | 1 | Yes | No |
| 13561635 | PREPARATIONS FOR EFFERVESCENT FORMULATIONS COMPRISING CEPHALOSPORIN AND USES THEREOF | July 2012 | September 2014 | Allow | 26 | 2 | 1 | Yes | Yes |
| 13489208 | MICROCAPSULES WITH ACETYLENE CARBAMIDE-POLYUREA POLYMERS AND FORMULATIONS THEREOF FOR CONTROLLED RELEASE | June 2012 | June 2014 | Allow | 25 | 2 | 0 | Yes | Yes |
| 13481495 | Systems and Methods for Inhibiting Formation of Stretch Marks | May 2012 | July 2013 | Allow | 14 | 1 | 1 | Yes | No |
| 13254115 | SUSTAINED RELEASE DOSAGE FORM | November 2011 | September 2014 | Allow | 36 | 2 | 0 | Yes | No |
| 13204219 | AGENT FOR INHIBITING PRODUCTION OF HEPATITIS C VIRUS AND ITS USE | August 2011 | June 2014 | Allow | 35 | 2 | 0 | No | No |
| 13195373 | MICROPARTICLE DISPERSION LIQUID MANUFACTURING METHOD AND MICROPARTICLE DISPERSION LIQUID MANUFACTURING APPARATUS | August 2011 | June 2013 | Allow | 23 | 3 | 0 | Yes | No |
| 12914345 | Oral Dosage Forms for Delivery of Therapeutic Agents | October 2010 | April 2016 | Allow | 60 | 2 | 0 | No | Yes |
| 12906455 | NOVEL WATER-RESISTANT SUNSCREEN COMPOSITION | October 2010 | June 2012 | Allow | 20 | 1 | 0 | Yes | No |
| 12867935 | Sustained Release Solid Formulations and Methods of Manufacturing the Same | August 2010 | July 2014 | Allow | 47 | 2 | 1 | Yes | No |
| 12770591 | IMPLANTABLE MEDICAL DEVICES COMPRISING POLY[L-LACTIDE-CO-(3,6-DIALKYL-1,4-DIOXANE-2,5-DIONE)] | April 2010 | July 2012 | Allow | 27 | 2 | 0 | Yes | No |
| 12739395 | NANOPARTICLE COMPOSITION AND PROCESS THEREOF | April 2010 | March 2014 | Allow | 47 | 3 | 1 | Yes | No |
| 12753161 | Hair Preparation Containing Two Copolymers | April 2010 | December 2014 | Allow | 56 | 5 | 1 | Yes | No |
| 12731838 | USE OF A POLYPHENOL-RICH PLANT EXTRACT AS ANTIOXIDANT IN COMBINATION WITH A HYDRATING OR HUMECTANT AGENT | March 2010 | January 2012 | Allow | 22 | 2 | 1 | Yes | No |
| 12695991 | SURFACE MODIFIED NANOPARTICLES, METHODS OF THEIR PREPARATION, AND USES THEREOF FOR GENE AND DRUG DELIVERY | January 2010 | March 2012 | Allow | 25 | 1 | 1 | Yes | No |
| 12644618 | DETERGENT COSMETIC COMPOSITION COMPRISING AT LEAST FOUR SURFACTANTS, AT LEAST ONE CATIONIC POLYMER AND AT LEAST ONE ZINC SALT | December 2009 | January 2014 | Allow | 48 | 2 | 1 | Yes | No |
| 12594509 | PEARLESCENT PIGMENTS CONTAINING COSMETIC COMPOSITIONS | October 2009 | March 2014 | Allow | 53 | 3 | 1 | Yes | No |
| 12306371 | GRANULE AND PREPARATION METHOD THEREOF | August 2009 | August 2014 | Allow | 60 | 4 | 1 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner PARK, HAEJIN S.
With a 75.0% reversal rate, the PTAB has reversed the examiner's rejections more often than affirming them. This reversal rate is in the top 25% across the USPTO, indicating that appeals are more successful here than in most other areas.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 50.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the top 25% across the USPTO, indicating that filing appeals is particularly effective here. The act of filing often prompts favorable reconsideration during the mandatory appeal conference.
✓ Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.
✓ Filing a Notice of Appeal is strategically valuable. The act of filing often prompts favorable reconsideration during the mandatory appeal conference.
Examiner PARK, HAEJIN S works in Art Unit 1614 and has examined 109 patent applications in our dataset. With an allowance rate of 78.9%, this examiner has a below-average tendency to allow applications. Applications typically reach final disposition in approximately 34 months.
Examiner PARK, HAEJIN S's allowance rate of 78.9% places them in the 40% percentile among all USPTO examiners. This examiner has a below-average tendency to allow applications.
On average, applications examined by PARK, HAEJIN S receive 2.10 office actions before reaching final disposition. This places the examiner in the 70% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.
The median time to disposition (half-life) for applications examined by PARK, HAEJIN S is 34 months. This places the examiner in the 22% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +37.7% benefit to allowance rate for applications examined by PARK, HAEJIN S. This interview benefit is in the 88% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 32.4% of applications are subsequently allowed. This success rate is in the 61% percentile among all examiners. Strategic Insight: RCEs show above-average effectiveness with this examiner. Consider whether your amendments or new arguments are strong enough to warrant an RCE versus filing a continuation.
This examiner enters after-final amendments leading to allowance in 33.3% of cases where such amendments are filed. This entry rate is in the 41% percentile among all examiners. Strategic Recommendation: This examiner shows below-average receptiveness to after-final amendments. You may need to file an RCE or appeal rather than relying on after-final amendment entry.
When applicants request a pre-appeal conference (PAC) with this examiner, 0.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 0% percentile among all examiners. Note: Pre-appeal conferences show limited success with this examiner compared to others. While still worth considering, be prepared to proceed with a full appeal brief if the PAC does not result in favorable action.
This examiner withdraws rejections or reopens prosecution in 66.7% of appeals filed. This is in the 42% percentile among all examiners. Of these withdrawals, 37.5% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows below-average willingness to reconsider rejections during appeals. Be prepared to fully prosecute appeals if filed.
When applicants file petitions regarding this examiner's actions, 54.5% are granted (fully or in part). This grant rate is in the 68% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.
Examiner's Amendments: This examiner makes examiner's amendments in 1.8% of allowed cases (in the 76% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 2.3% of allowed cases (in the 67% percentile). This examiner issues Quayle actions more often than average when claims are allowable but formal matters remain (MPEP § 714.14).
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.